The patient may have underlying severe CAD, but on occasion nonobstructive or no CAD. Type 2: MI secondary to ischemic imbalance In instances of myocardial injury with necrosis where a condition other than CAD contributes to an imbalance between MVO2 , eg, coronary endothelial dysfunction, coronary artery spasm, coronary embolism, tachy-/bradyarrhythmias, anemia, respiratory failure, hypotension, and hypertension with or without LVH. Type 3: MI resulting in death when biomarker values are unavailable Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic electrocardiographic changes or new LBBB, but death occurred before blood samples could be obtained, before cardiac biomarker could rise, or in rare cases where blood was not collected for cardiac biomarker testing. Type 4a: MI related to PCI MI associated with PCI is arbitrarily defined by elevation of cTn values >5 99th percentile URL in patients with normal baseline values (<99th percentile URL) or a rise of cTn values >20% if baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial ischemia, (ii) new ischemic electrocardiographic changes or new LBBB, (iii) angiographic loss of patency of a major coronary artery or a side branch or persistent slow or no flow or embolization, or (iv) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality is required. Type 4b: MI related to stent thrombosis MI associated with stent thrombosis is detected by coronary angiography or autopsy in the setting of myocardial ischemia and with a rise and/or fall of cardiac biomarker values with 1 value above the 99th percentile URL. Type 5: MI related to CABG MI associated with CABG is arbitrarily defined by elevation of cardiac biomarker values >10 99th percentile URL in patients with normal baseline cTn values (<99th percentile URL). 